- Obama’s regulatory agenda will cost U.S. economy $143B next year: report
- Patriot Act author on James Clapper: Fire, prosecute him
- Russia P.M. Medvedev: No amnesty for political prisoners
- Michigan GOP Senate hopeful reminds government is the ‘servant’
- Christmas, by Congress: Members mull a 15-cent tax on trees
- U.S. unemployment falls to five-year low of 7 percent; 203K jobs added
- World mourns Nelson Mandela and celebrates his life; burial set for Dec. 15
- Bill O’Reilly reminds: Nelson Mandela ‘was a communist’
- John Boehner says GOP should support gay candidates: ‘I do’
- Grass-Whopper: Pan-fried cricket burgers go over big in New York City
Germany orders recall of some Novartis flu shots
Question of the Day
BERLIN (AP) - German authorities ordered a recall Thursday of some batches of Novartis flu vaccine as a precautionary measure after the company reported the appearance of small particles in the manufacturing process.
The Paul Ehrlich Institute, which is part of the country’s Ministry of Health, said there had been no reports of particle formation in Germany or of any serious side effects during the current flu season.
“However, in the interest of risk prevention and consumer safety it is necessary to cancel the approval for certain vaccines, since the formation of particles in the vaccine and therefore the risk of serious side effects cannot be ruled out,” Institute President Prof. Klaus Cichutek said in a statement.
The decision affects four batches of the influenza vaccine Begripal and one batch of Fluad. It does not affect the seasonal vaccine Optaflu.
Italy’s health ministry banned the sale of four Novartis flu drugs on Wednesday. These included Fluad and Begripal _ sold as Aggripal in Italy _ as well as two others: Influpozzi Adiuvato and Influpozzi Subunita.
Switzerland’s regulator Swissmedic also suspended deliveries of flu vaccines from Novartis as a preventive measure.
Britain’s Medicines and Healthcare products Regulatory Agency said there was no evidence yet to pull the vaccines off the market but added it was gathering further information on the Novartis vaccines.
The Swiss pharmaceutical company said Thursday it was cooperating with the Ministry of Health in Italy, where the vaccines are produced, and was committed to providing vaccines to patients for the current flu season. There had been no adverse effects reported so far from more than 1 million doses of Agrippal/Begripal and Fluad administered, the Basel-based company said.
“Novartis confirms that these particles can occur in the vaccine manufacturing process and is confident that there is no impact on the safety or efficacy of the vaccine,” it said in a statement.
- Spike in battlefield deaths linked to restrictive rules of engagement
- Bill OReilly reminds: Nelson Mandela was a communist
- Activists urge Obama to go rogue, sidestep Congress
- Colorado judge: Bakery owner discriminated against gay couple
- U.S. pilot scares off Iranians with 'Top Gun'-worthy stunt: 'You really ought to go home'
- Obama administration issues permits for wind farms to kill more eagles
- Rush Limbaugh: Obama trying to make Mandela death about himself
- 'Hunger Games' delivers Obama's message on income inequality
- U.S. debt jumps a record $328 billion tops $17 trillion for first time
- Kill team: Obama war chiefs widen drone death zones
Independent voices from the The Washington Times Communities
The Constitution: Every issue, every time. No exceptions, no excuses. And how to get from here to there.
Why can’t humans just be free to be humans?
Get in the middle of all the action inside and outside the boxing ring.
Find the latest news and happening that effect those in the Washington D.C., Northern Virginia and Maryland Metro region.
White House pets gone wild!